Physician profile
Mark A Ciminelli
NPI 1982657003
$3,786.45
in general payments reported to CMS, 2019-2025
29 companies · $17.76 in 2025
The $17.76 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $678 · 2021: $1,283 · 2022: $712 · 2025: $17.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $551.89 | 2019-2022 | |
| Biotronik INC. | $381.76 | 2019-2022 | |
| Astellas Pharma US INC | $288.84 | 2019-2021 | |
| Amarin Pharma, INC. | $282.27 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $266.15 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $185.28 | 2019-2021 | |
| Amgen INC. | $183.20 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.86 | 2019-2022 | |
| Esperion Therapeutics, INC. | $177.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $172.68 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $157.81 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $139.37 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.52 | 2021-2022 | |
| Boston Scientific Corporation | $93.98 | 2019-2025 | Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $93.90 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $70.35 | 2019-2022 | |
| Pfizer INC. | $64.23 | 2019-2022 | |
| Edwards Lifesciences Corporation | $63.70 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.00 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $47.09 | 2019 | |
| Lundbeck LLC | $40.24 | 2019 | |
| Abbott Laboratories | $38.61 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $29.03 | 2019 | |
| Alnylam Pharmaceuticals INC. | $27.31 | 2021 | |
| Vifor Pharma, INC. | $23.96 | 2019 | |
| Infobionic, INC | $17.83 | 2021 | |
| Novo Nordisk INC | $14.60 | 2021 | |
| Gilead Sciences, INC. | $14.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ciminelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.